; (B) in the paragraph (4) inserted by such section 3(1), by inserting application before under section 351(k) of the Public Health Service Act ; (C) in the paragraph (5) inserted by such section 3(1), by striking for licensure of a biological product under section 351(k) of the Public Health Service Act and inserting under section 351(k) of the Public Health Service Act for licensure of a biological product as biosimilar to, or interchangeable with, a reference product ; (D) in paragraph (7), as redesignated and amended by such section 3(1), by striking or under section 351(a) of the Public Health Service Act and inserting or the owner, or exclusive licensee, of a patent included in a list provided under section 351(l)(3) of the Public Health Service Act ; and (E) in the paragraph (12) added by such section 3(1), by striking means a brand name drug for which a license is in effect under section 351(a) and inserting has the meaning given such term in section 351(i) ; and (2) in section 1112, as amended by section 3(2) of the Patient Right to Know Drug Prices Act— (A) in subsection (a)— (i) in paragraph (1), by striking for which a statement under section 351(l)(3)(B)(ii)(I) of the Public Health Service Act has been provided ; (ii) in paragraph (2)— (I) in subparagraph (C)(i), by striking brand name and inserting listed ; and (II) by amending clause (ii) of subparagraph (C) to read as follows: (ii) any of the time periods referred to in section 351(k)(6) of the Public Health Service Act as such period applies to such biosimilar biological product application or to any other biosimilar biological product application based on the same reference product. ; (B) in subsection (b)— (i) in the subsection heading, by inserting or Biosimilar Biological Product Applicant after Applicant